Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review.
Antibiotic stewardship program
Antimicrobial resistance
Antimicrobial stewardship
Economic evaluation
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
08
2018
accepted:
11
01
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
3
3
2020
Statut:
epublish
Résumé
Hospital antimicrobial stewardship programs (ASPs) aim to promote judicious use of antimicrobials to combat antimicrobial resistance. For ASPs to be developed, adopted, and implemented, an economic value assessment is essential. Few studies demonstrate the cost-effectiveness of ASPs. This systematic review aimed to evaluate the economic and clinical impact of ASPs. An update to the Dik et al. systematic review (2000-2014) was conducted on EMBASE and Medline using PRISMA guidelines. The updated search was limited to primary research studies in English (30 September 2014-31 December 2017) that evaluated patient and/or economic outcomes after implementation of hospital ASPs including length of stay (LOS), antimicrobial use, and total (including operational and implementation) costs. One hundred forty-six studies meeting inclusion criteria were included. The majority of these studies were conducted within the last 5 years in North America (49%), Europe (25%), and Asia (14%), with few studies conducted in Africa (3%), South America (3%), and Australia (3%). Most studies were conducted in hospitals with 500-1000 beds and evaluated LOS and change in antibiotic expenditure, the majority of which showed a decrease in LOS (85%) and antibiotic expenditure (92%). The mean cost-savings varied by hospital size and region after implementation of ASPs. Average cost savings in US studies were $732 per patient (range: $2.50 to $2640), with similar trends exhibited in European studies. The key driver of cost savings was from reduction in LOS. Savings were higher among hospitals with comprehensive ASPs which included therapy review and antibiotic restrictions. Our data indicates that hospital ASPs have significant value with beneficial clinical and economic impacts. More robust published data is required in terms of implementation, LOS, and overall costs so that decision-makers can make a stronger case for investing in ASPs, considering competing priorities. Such data on ASPs in lower- and middle-income countries is limited and requires urgent attention.
Sections du résumé
Background
Hospital antimicrobial stewardship programs (ASPs) aim to promote judicious use of antimicrobials to combat antimicrobial resistance. For ASPs to be developed, adopted, and implemented, an economic value assessment is essential. Few studies demonstrate the cost-effectiveness of ASPs. This systematic review aimed to evaluate the economic and clinical impact of ASPs.
Methods
An update to the Dik et al. systematic review (2000-2014) was conducted on EMBASE and Medline using PRISMA guidelines. The updated search was limited to primary research studies in English (30 September 2014-31 December 2017) that evaluated patient and/or economic outcomes after implementation of hospital ASPs including length of stay (LOS), antimicrobial use, and total (including operational and implementation) costs.
Results
One hundred forty-six studies meeting inclusion criteria were included. The majority of these studies were conducted within the last 5 years in North America (49%), Europe (25%), and Asia (14%), with few studies conducted in Africa (3%), South America (3%), and Australia (3%). Most studies were conducted in hospitals with 500-1000 beds and evaluated LOS and change in antibiotic expenditure, the majority of which showed a decrease in LOS (85%) and antibiotic expenditure (92%). The mean cost-savings varied by hospital size and region after implementation of ASPs. Average cost savings in US studies were $732 per patient (range: $2.50 to $2640), with similar trends exhibited in European studies. The key driver of cost savings was from reduction in LOS. Savings were higher among hospitals with comprehensive ASPs which included therapy review and antibiotic restrictions.
Conclusions
Our data indicates that hospital ASPs have significant value with beneficial clinical and economic impacts. More robust published data is required in terms of implementation, LOS, and overall costs so that decision-makers can make a stronger case for investing in ASPs, considering competing priorities. Such data on ASPs in lower- and middle-income countries is limited and requires urgent attention.
Identifiants
pubmed: 30805182
doi: 10.1186/s13756-019-0471-0
pii: 471
pmc: PMC6373132
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Déclaration de conflit d'intérêts
Not applicable.Not applicable.At the time this manuscript was completed Ansari W and Charbonneau C were employees of Pfizer, Inc. Nathwani D is a key opinion leader on the topic of antimicrobial stewardship and a paid consultant for Pfizer Inc. Stephens J is a health economic consultant and is a managing partner and co-owner of Pharmerit International. Varghese D and Martin S were employees of Pharmerit International who were paid consultants in connection with this study.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Am J Health Syst Pharm. 2014 Jul 1;71(13):1136-9
pubmed: 24939504
J Trauma Acute Care Surg. 2012 Dec;73(6):1484-90
pubmed: 23064610
Adv Ther. 2015 Jan;32(1):69-85
pubmed: 25620538
Arch Intern Med. 2001 Aug 13-27;161(15):1897-902
pubmed: 11493132
Am J Health Syst Pharm. 2012 Nov 1;69(21):1910-4
pubmed: 23111676
J Antimicrob Chemother. 2004 May;53(5):853-9
pubmed: 15044426
Lancet Infect Dis. 2017 Sep;17(9):990-1001
pubmed: 28629876
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4840-52
pubmed: 27246783
Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93
pubmed: 16603606
Infect Control Hosp Epidemiol. 2012 Apr;33(4):338-45
pubmed: 22418628
Clin Infect Dis. 2004 Feb 1;38(3):348-56
pubmed: 14727204
Medicine (Baltimore). 2016 Mar;95(9):e2753
pubmed: 26945362
Expert Rev Anti Infect Ther. 2012 Apr;10(4):445-57
pubmed: 22512754
Infect Control Hosp Epidemiol. 2003 Sep;24(9):699-706
pubmed: 14510254
J Hosp Infect. 2011 Aug;78(4):289-92
pubmed: 21636167
Hosp Pharm. 2013 Oct;48(9):744-52
pubmed: 24421548
Patient Saf Surg. 2014 Sep 17;8(1):37
pubmed: 25431623
Yakugaku Zasshi. 2010 Aug;130(8):1105-11
pubmed: 20686215
Fam Pract. 2016 Apr;33(2):192-9
pubmed: 26797464
Clin Infect Dis. 2003 Sep 1;37(5):742-3
pubmed: 12942418
BMC Infect Dis. 2014 Apr 15;14:201
pubmed: 24731220
BMC Health Serv Res. 2011 Apr 13;11:75
pubmed: 21489236
J Am Geriatr Soc. 2004 Jan;52(1):112-6
pubmed: 14687324
BMC Health Serv Res. 2016 Jul 27;16:311
pubmed: 27464508
J Clin Microbiol. 2000 Aug;38(8):2824-8
pubmed: 10921934
J Clin Microbiol. 2016 Dec 28;55(1):60-67
pubmed: 27795335
Clin Microbiol Infect. 2014 Oct;20(10):993-1000
pubmed: 24673973
Infect Control Hosp Epidemiol. 2016 Apr;37(4):425-32
pubmed: 26738993
Saudi Med J. 2016 Dec;37(12):1350-1358
pubmed: 27874151
Int J Clin Pract. 2012 Oct;66(10):999-1008
pubmed: 22846073
Lancet Infect Dis. 2016 Sep;16(9):1017-1025
pubmed: 27312577
Infect Control Hosp Epidemiol. 2017 Mar;38(3):259-265
pubmed: 27917735
Clin Infect Dis. 2003 Jul 15;37(2):180-6
pubmed: 12856209
Braz J Infect Dis. 2016 May-Jun;20(3):255-61
pubmed: 27094234
Ann Pharmacother. 2012 Nov;46(11):1484-90
pubmed: 23136356
Infect Control Hosp Epidemiol. 2005 Jan;26(1):81-7
pubmed: 15693413
Pharm World Sci. 2007 Oct;29(5):565-72
pubmed: 17610145
J Hosp Infect. 2003 Mar;53(3):177-82
pubmed: 12623317
Infect Control Hosp Epidemiol. 2012 Apr;33(4):405-8
pubmed: 22418638
Eur Urol. 2016 Feb;69(2):276-83
pubmed: 26001610
Am J Health Syst Pharm. 2012 Jul 1;69(13):1142-8
pubmed: 22722593
Open Forum Infect Dis. 2015 May 12;2(2):ofv064
pubmed: 26110166
J Infect. 2014 Sep;69(3):216-25
pubmed: 24841135
World Hosp Health Serv. 2013;49(2):18-21
pubmed: 24228343
Int J Antimicrob Agents. 2016 Jan;47(1):91-6
pubmed: 26706421
Am J Health Syst Pharm. 2016 Mar 1;73(5 Suppl 1):S8-13
pubmed: 26896530
Intern Med J. 2014 Sep;44(9):903-10
pubmed: 24963727
Infection. 2013 Jun;41(3):621-8
pubmed: 23463185
Expert Rev Anti Infect Ther. 2015 Feb;13(2):279-89
pubmed: 25495147
Med J Aust. 2003 Mar 3;178(5):207-9
pubmed: 12603182
Int J Clin Pharmacol Ther. 2012 Feb;50(2):136-41
pubmed: 22257579
Eur J Clin Microbiol Infect Dis. 2009 Dec;28(12):1447-56
pubmed: 19727869
Infect Dis (Lond). 2016 Oct;48(10):732-7
pubmed: 27196015
J Antimicrob Chemother. 2017 Nov 1;72(11):3213-3221
pubmed: 28981722
Crit Care Med. 2013 Sep;41(9):2099-107
pubmed: 23873275
Infect Control Hosp Epidemiol. 2012 Apr;33(4):398-400
pubmed: 22418636
PLoS One. 2013 Nov 11;8(11):e78942
pubmed: 24244390
PLoS One. 2015 May 08;10(5):e0126106
pubmed: 25955494
Antibiotics (Basel). 2013 Apr 24;2(2):256-64
pubmed: 27029302
Infect Control Hosp Epidemiol. 2006 Apr;27(4):378-82
pubmed: 16622816
Clin Med (Lond). 2013 Oct;13(5):499-503
pubmed: 24115710
Infect Control Hosp Epidemiol. 2015 Jun;36(6):681-7
pubmed: 25783204
Clin Infect Dis. 2008 Sep 15;47(6):747-53
pubmed: 18680419
Pharm World Sci. 2000 Apr;22(2):53-8
pubmed: 10849923
Antimicrob Resist Infect Control. 2012 Oct 09;1(1):32
pubmed: 23043720
Am J Health Syst Pharm. 2014 Jun 15;71(12):1019-28
pubmed: 24865759
PLoS One. 2013 Dec 09;8(12):e79747
pubmed: 24348995
Pediatr Infect Dis J. 2016 Oct;35(10):1104-10
pubmed: 27254036
Pharmacotherapy. 2002 Apr;22(4):471-83
pubmed: 11939682
Arch Pathol Lab Med. 2013 Sep;137(9):1247-54
pubmed: 23216247
J Antimicrob Chemother. 2006 Jul;58(1):154-8
pubmed: 16636084
Pharmacotherapy. 2014 Nov;34(11):1141-50
pubmed: 25283969
Infect Control Hosp Epidemiol. 2008 May;29(5):457-61
pubmed: 18419372
Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):247-51
pubmed: 25123989
Am J Health Syst Pharm. 2014 Jun 1;71(11):943-9
pubmed: 24830998
Clin Infect Dis. 2015 Apr 15;60(8):1252-8
pubmed: 25595748
Can J Hosp Pharm. 2011 Sep;64(5):314-20
pubmed: 22479082
Am J Infect Control. 2013 Feb;41(2):145-8
pubmed: 22579261
J Infect Chemother. 2016 Jun;22(6):400-6
pubmed: 27062334
Infection. 2015 Aug;43(4):405-12
pubmed: 25588968
Int J Antimicrob Agents. 2015 Nov;46(5):594-5
pubmed: 26493229
Qual Saf Health Care. 2008 Oct;17(5):387-92
pubmed: 18842981
Braz J Infect Dis. 2016 Nov - Dec;20(6):631-634
pubmed: 27609214
Int J Clin Pharm. 2012 Apr;34(2):290-4
pubmed: 22382886
Clin Infect Dis. 2005 Nov 15;41(10):1438-44
pubmed: 16231254
Pharm World Sci. 2008 Dec;30(6):787-93
pubmed: 18493864
Infection. 2016 Jun;44(3):301-7
pubmed: 26475481
Clin Microbiol Infect. 2013 Jan;19(1):56-61
pubmed: 22551077
PLoS One. 2014 Feb 25;9(2):e88971
pubmed: 24586465
QJM. 2005 Oct;98(10):745-52
pubmed: 16126741
J Clin Pharm Ther. 2006 Apr;31(2):179-85
pubmed: 16635053
Diagn Microbiol Infect Dis. 2016 Feb;84(2):159-64
pubmed: 26639226
Clin Infect Dis. 2006 Mar 15;42(6):768-75
pubmed: 16477551
Pharmacotherapy. 2013 Jan;33(1):3-10
pubmed: 23307539
J Antimicrob Chemother. 2009 Jul;64(1):188-99
pubmed: 19401304
Ann Pharmacother. 2000 Feb;34(2):154-60
pubmed: 10676821
Pediatr Crit Care Med. 2016 Mar;17(3):187-93
pubmed: 26669645
Hosp Pharm. 2014 Oct;49(9):839-46
pubmed: 25477615
Braz J Infect Dis. 2015 May-Jun;19(3):246-52
pubmed: 25892314
Presse Med. 2014 Nov;43(11):e365-8
pubmed: 25201601
Front Microbiol. 2015 Apr 16;6:317
pubmed: 25932024
Pharm Pract (Granada). 2007;5(2):67-73
pubmed: 25214920
Crit Care. 2017 Jul 15;21(1):180
pubmed: 28709439
Infect Control Hosp Epidemiol. 2006 Mar;27(3):239-44
pubmed: 16532410
Infect Control Hosp Epidemiol. 2010 Jul;31(7):722-7
pubmed: 20497042
BMC Infect Dis. 2015 Oct 29;15:480
pubmed: 26511839
Crit Care. 2012 Nov 05;16(6):R216
pubmed: 23127353
Int J Infect Dis. 2013 Dec;17(12):e1212-7
pubmed: 24120217
BMJ Open. 2015 Feb 13;5(2):e006916
pubmed: 25681314
J Antimicrob Chemother. 2003 Nov;52(5):842-8
pubmed: 14563900
J Antimicrob Chemother. 2006 Sep;58(3):651-6
pubmed: 16867998
Int J Clin Pharm. 2011 Apr;33(2):208-14
pubmed: 21744190
Clin Infect Dis. 2010 Nov 1;51(9):1074-80
pubmed: 20879856
J Hosp Med. 2013 Jun;8(6):341-5
pubmed: 23553999
Mil Med. 2009 Feb;174(2):201-5
pubmed: 19317204
J Clin Diagn Res. 2015 Feb;9(2):FC05-9
pubmed: 25859466
Br J Neurosurg. 2017 Feb;31(1):16-20
pubmed: 27623701
Am J Infect Control. 2013 Nov;41(11):1069-72
pubmed: 23870295
J Am Med Inform Assoc. 2006 Jul-Aug;13(4):378-84
pubmed: 16622162
Clin Infect Dis. 2014 Sep 15;59(6):867-74
pubmed: 24928294
Hosp Pharm. 2014 May;49(5):444-8
pubmed: 24958956
N Engl J Med. 2010 Dec 23;363(26):2477-81
pubmed: 21142528
Diagn Microbiol Infect Dis. 2014 Feb;78(2):157-61
pubmed: 24316015
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):947-55
pubmed: 21904857
J Infect Public Health. 2018 May - Jun;11(3):310-313
pubmed: 28864362
Circulation. 2016 Nov 15;134(20):1568-1578
pubmed: 27840334
BMC Health Serv Res. 2005 Jun 29;5:48
pubmed: 15987523
Open Forum Infect Dis. 2015 Mar 23;2(2):ofv042
pubmed: 26380341
Am J Health Syst Pharm. 2000 Feb 1;57(3):268-74
pubmed: 10674779
J Pediatr Pharmacol Ther. 2012 Apr;17(2):159-65
pubmed: 23118668
Diagn Microbiol Infect Dis. 2016 Jan;84(1):63-68
pubmed: 26603136
Med Mal Infect. 2011 Oct;41(10):532-9
pubmed: 21907511
Am J Health Syst Pharm. 2014 Feb 1;71(3):227-30
pubmed: 24429017
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Am J Health Syst Pharm. 2012 Sep 1;69(17):1500-8
pubmed: 22899745
Clin Infect Dis. 2001 Aug 1;33(3):289-95
pubmed: 11438891
J Clin Microbiol. 2016 Oct;54(10):2455-63
pubmed: 27487951
Ann Intern Med. 2014 Nov 18;161(10 Suppl):S53-8
pubmed: 25402404
Medicine (Baltimore). 2015 Sep;94(39):e1454
pubmed: 26426609
BMC Med Inform Decis Mak. 2016 Mar 15;16:34
pubmed: 26976388
Infect Control Hosp Epidemiol. 2013 Jun;34(6):573-80
pubmed: 23651887
BMC Infect Dis. 2015 Oct 26;15:458
pubmed: 26503359
J Healthc Qual. 2017 Jul/Aug;39(4):e59-e69
pubmed: 27811579
J Antimicrob Chemother. 2000 Mar;45(3):387-94
pubmed: 10702564